Moderna Inc's COVID-19 vaccine showed promise against the Delta variant first identified in India in a lab study, with a modest decrease in response compared to the original strain, the drugmaker said on Tuesday.
The study was conducted on blood serum from eight participants obtained one week after they received the second dose of the vaccine, mRNA-1273.